Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Cell Biochem. 2019 May 20;120(10):16741–16749. doi: 10.1002/jcb.28932

Figure 1. Inhibition of HMGB1 and its receptors alters osteoclast differentiation in a stage-dependent manner.

Figure 1.

(A) Non-adherent BMCs treated with rabbit IgG control or anti-HMGB1 antibodies. Bars represent mean ± S.D. (n=6). *p<0.05 vs vehicle rabbit IgG control treated cells by t-test. Representative osteoclast images are shown. (B) Illustration of the experimental design testing the effects of inhibitor treatment at different stages of osteoclast differentiation and (C) osteoclast numbers reported as fold changes. Inhibitors or vehicle were added to BMMs (day 1-3) or pre-osteoclasts (day 3-5) HMGB1 receptor inhibitor- (Azeliragon and LPS-Rs) treated non-adherent BMCs at different stages of differentiation. *p<0.05 vs vehicle control treated non-adherent BMCs by one-way ANOVA. Bars represent mean ± S.D. (n=6).